Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Minneapolis, Minnesota

This page shows live ClinicalTrials.gov search results for Minneapolis, Minnesota, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
7865
Shown on this page
12
Current sort
Recently updated
Location scope
Minneapolis, MN
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Minneapolis, Minnesota. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 445–456 of 7,865 matching trials in Minneapolis, MN.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search
Recruiting Phase 3 Interventional

A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

NCT06873945
View directory record Official record
Conditions
Alopecia Areata
Interventions
Ritlecitinib 100 mg, Ritlecitinib 50 mg, Placebo - 100 mg, Placebo - 50 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
674 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
60
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Brea, California + 39 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 7, 2026, 2:47 PM EST
Recruiting Early Phase 1 Interventional

Effect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart Failure

NCT06507657
View directory record Official record
Conditions
Hypertension, Cardiovascular Diseases
Interventions
empagliflozin, Placebo tablet
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
60 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 7, 2026, 2:47 PM EST
Recruiting Phase 1 Interventional

Coordinated Reset Deep Brain Stimulation for Essential Tremor

NCT05897775
View directory record Official record
Conditions
Essential Tremor, Upper Extremity Essential Tremor
Interventions
Deep brain stimulation
Device
Lead sponsor
University of Minnesota
Other
Eligibility
21 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 7, 2026, 2:47 PM EST
Active, not recruiting Not applicable Interventional Results available

SELUTION SLR™ 014 In-stent Restenosis

NCT04280029
View directory record Official record
Conditions
Coronary Restenosis
Interventions
SELUTION SLR 014 DEB, Standard of Care
Device
Lead sponsor
M.A. Med Alliance S.A.
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
34
States / cities
Loma Linda, California • Los Angeles, California • Torrance, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 7, 2026, 2:47 PM EST
Recruiting No phase listed Observational

Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

NCT00736749
View directory record Official record
Conditions
Hematopoietic Cell Transplantation Recipient, Leukemia, Solid Tumor
Interventions
Assessment of Therapy Complications, Questionnaire Administration
Procedure · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Not listed
Enrollment
25,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
163
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 124 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 7, 2026, 2:47 PM EST
Recruiting No phase listed Observational

Product Surveillance Registry

NCT01524276
View directory record Official record
Conditions
Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders, Digestive Disorders, Intracranial Aneurysm, Mechanical Circulatory Support, Respiratory Therapy, Aortic, Peripheral Vascular and Venous Disorders, Minimally Invasive Surgical Procedures, Diagnostic Techniques and Procedures, Surgical Procedures, Operative, Renal Insufficiency, Neurovascular, Coronary Artery Disease, Ear, Nose and Throat Disorder
Interventions
Not listed
Lead sponsor
Medtronic
Industry
Eligibility
Not listed
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2040
U.S. locations
136
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 133 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 7, 2026, 2:47 PM EST
Recruiting Phase 3 Interventional

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

NCT07213674
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Xaluritamig, Abiraterone acetate, Docetaxel, Cabazitaxel
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Male only
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
46
States / cities
Goodyear, Arizona • Tucson, Arizona • Duarte, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 7, 2026, 2:47 PM EST
Recruiting Phase 2 Interventional

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

NCT06890338
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Neoadjuvant
Interventions
Carboplatin, Mirvetuximab Soravtansine, Bevacizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
73
States / cities
Birmingham, Alabama • Mobile, Alabama • Irvine, California + 65 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 7, 2026, 2:47 PM EST
Not yet recruiting Phase 4 Interventional

GLP-1 Plus Lifestyle for Overall Wellness: Find Your Way Forward

NCT06977438
View directory record Official record
Conditions
Obesity, Childhood
Interventions
Semaglutide
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 18 Years
Enrollment
1,020 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 7, 2026, 2:47 PM EST
Recruiting Not applicable Interventional

Microbiome-targeted Diet Therapy in Ulcerative Colitis

NCT07520461
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
High Protein, High Fiber (HPHF) Diet
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 7, 2026, 2:47 PM EST
Recruiting Not applicable Interventional

Advancing Clinical Heart Failure Outcomes Leveraging Defibrillation Lead Implant System for Left Bundle Branch Area Pacing

NCT07526896
View directory record Official record
Conditions
Heart Failure, Systolic Bundle Branch Block, Left
Interventions
LBBAP Therapy, LOT-CRT, ICD
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 7, 2026, 2:47 PM EST
Completed Phase 2 Interventional Results available

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine

NCT06848075
View directory record Official record
Conditions
Migraine
Interventions
Elismetrep (K-304) 2 mg, Elismetrep (K-304) 5 mg, Elismetrep (K-304) 10 mg, Elismetrep (K-304) 20 mg, Placebo
Drug
Lead sponsor
TriGemX Bio, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 7, 2026, 2:47 PM EST